2021-138: JPV-Based Vaccine Vectors

Non-segmented Negative Single-stranded Virus based vaccine vector system with a large antigen sequence insertion capacityJPV-based vaccine for Avian Influenza (H5N1) can elicit an immune response to H5N1 in mouse and rhesus macaquesMice inoculated with…
  • Non-segmented Negative Single-stranded Virus based vaccine vector system with a large antigen sequence insertion capacity
  • JPV-based vaccine for Avian Influenza (H5N1) can elicit an immune response to H5N1 in mouse and rhesus macaques
  • Mice inoculated with the JPV-based H5N1 vaccine mice survived a lethal H5N1 challenge

Abstract

In 2021, the global market for vaccines totaled USD 38.2 billion. Non-segmented Negative Single-stranded Virus (NNSV) based vaccine vectors are a superior vaccine vector option, as they have no DNA intermediate attenuating the risk of gene insertion to the host genome. NNSV based vaccines are currently in use for veterinary, agriculture and human inoculations. One limitation with current NNSV vector systems, such as PIV5, is a small antigen sequence insertion capacity. This technology is takes advantage of a new NNSV vector system, J Paramyxovirus (JPV), to develop a vaccine against avian influenza, H5N1. This vaccine, delivered intranasally, drives a robust immune response in mice and rhesus macaques against H5N1. H5N1 has had sporadic outbreak since 1961, most recently occurring from 2003-2010. H5N1 can spread from infected birds to humans, as well as mammal to humans, with high mortality in individuals aged 10-19 and young adults. [CA1] Efforts to eradicate H5N1 have resulted in antiviral resistant strains, and current vaccines for H5N1 require several high doses for 50% protection. Using the JPV vector system to drive expression in the respiratory tract, this vaccine provided full protection through a lethal challenge to H5N1 in mice and produced H5N1 neutralizing titers in rhesus macaques. These data show proof-of-principal that this vaccine system is effective at generating immune response in mouse and non-human primates models. In addition, antibodies against JPV have been found in a wide range of mammals, from mice to pigs to humans, indicating large host range and therefore therapeutic applications. The important fact about this vaccine vector is that it has a larger antigen sequence insertion capacity than PIV5 vaccine vector. Influenza was used as an example that this system would work.

Website

https://uga.flintbox.com/technologies/8706BDBC588840BC9E2736C411B38D0A

Advantages

  • JPV vector has wide range of potential mammalian host systems
  • JPV based H5N1 vaccine requires only a single inoculation for effective immunization in mice
  • JPV based H5N1 vaccine generated IgG and IgA response to H5N1 in rhesus macaques

Potential Applications

JPV vector can be used to generate vaccines for larger antigen sequences than the current PIV5 vector.

Contact Information

Name: Cory Acuff

Email: cacuff@uga.edu

Phone: 706-542-5682